Meeting

Optogenerapy > Meeting
Optogenerapy final meeting

Eurecat has hosted the 37-month meeting of Optogenerapy project in its facilities in Cerdanyola del Valles. On January 23-24, partners reviewed the work done during the project and prepared themselves for the review meeting taking place in March. On January 24, a final public event to present the project results took place, gathering almost 60 persons interested in the project. ...

Read More
Optogenerapy consortium meeting

Optogenerapy project partners gathered in Barcelona on Oct 21-22th to present the project’s latest results for the development of a bio-electronic implant for patients with Multiple Sclerosis. During the meeting, partners reviewed the work done in each of the Work Packages and set up the next steps to be achieved until the end of the project in January 2020.  On Monday 21st, partners also organized a workshop with...

Read More
optogenerapy_meeting_1year_INSERM

Paris, 23rd February, 2017 – Optogenerapy’s consortium has met in Paris at INSERM facilities for the project’s third meeting, marking one year after the start of the project. At the meeting, partners reviewed the advances in each of the work packages and planned and prepared upcoming milestones and tasks.   During the first year of the project, partners addressed the design and development of the implant, including...

Read More

Barcelona, 11th September, 2017 – The Optogenerapy consortium will be gathered together for its second meeting after the project’s kick-off in February. The meeting, hosted by the project’s partner ETHZ, the Swiss Federal Institute of Technology Zurich, will take place in Basel on September 14th and 15th.   The first six months of the project have been busy in defining specifications and designing the first pieces of...

Read More

Barcelona 20th February, 2017 - Researchers from eleven institutions and companies in seven different European countries met at Eurecat’s facilities in Cerdanyola del Vallès (Barcelona) to launch the Optogenerapy project, which aims to develop optogenetic cellular therapy implants as a new treatment for Multiple Sclerosis.   The devices, based on technology developed at the Swiss Federal Institute of Technology in Basel, member of the consortium, will enable the...

Read More
Do NOT follow this link or you will be banned from the site!